Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A mood stabilizer used to treat bipolar affective disorders may also help treat acute kidney injury, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings are significant because there are no effective therapies for AKI.
AKI, an abrupt decline in kidney function, is an increasingly prevalent and potentially serious condition that can arise following trauma, sepsis, major surgery, or exposure to drugs that are toxic to the kidneys. Once the injury develops, patients have few established treatment options besides supportive care. AKI afflicts about 5% of all hospitalized patients and approximately 25% to 30% of patients in intensive care units. AKI is one of the most expensive conditions seen in US hospitals, costing the facilities several billions of dollars each year.
Research has shown that glycogen synthase kinase (GSK) 3β is an enzyme that plays a major role in the development of AKI. Fortunately, GSK3β can be blocked by using inhibitors, including novel small molecule chemical compounds and lithium.
Lithium is an FDA-approved mood stabilizer safely used for the past 50 years to treat bipolar affective disorders, but it carries significant side effects when used long-term. Hui Bao, MD, PhD, Rujun Gong, MD, PhD (Rhode Island Hospital, Brown University School of Medicine), and their colleagues discovered that giving mice a single low dose of lithium following AKI blocks GSK3β in injured kidneys, promotes kidney repair, and accelerates the recovery of kidney function.
"Our work suggests that lithium might represent a novel, pragmatic, and affordable therapy to improve kidney recovery after AKI," said Dr. Gong.
More pre-clinical studies are warranted to see if targeting GSK3β with lithium can improve long-term kidney health. Also, clinical trials are needed to determine the appropriate dose of lithium to promote kidney recovery following AKI in humans.
In an accompanying editorial, Man Livingston, PhD and Zheng Dong, PhD (Medical College of Georgia at Georgia Regents University and Charlie Norwood Veterans Affairs Medical Center) noted that "this study, by demonstrating the effect of lithium on tubular regeneration and repair in AKI, has significantly extended our knowledge of this drug and may broaden its potential therapeutic applications in kidney diseases."
Study co-authors include Yan Ge, MS, Zhen Wang, MD, PhD, Shougang Zhuang, MD, PhD, Lance Dworkin, MD, and Ai Peng, MD.
Disclosures: This study was made possible in part by the funding from the US National Institutes of Health grant R01DK092485 and the International Society of Nephrology (ISN) Sister Renal Center Trio Program. Dr. Hui Bao was an ISN fellow and a visiting nephrologist at Brown Medical School from Tongji University in Shanghai, China under the support of the ISN fellowship.
The article: "Delayed Administration of a Single Dose of Lithium Promotes Recovery from AKI." JASN ASN.2013040350; published ahead of print January 9, 2014, doi:10.1681/ASN.2013040350
The editorial: "Lithium in Kidney Diseases: Big Roles for the Smallest Metal." JASN ASN.2013111216; published ahead of print January 9, 2014, doi:10.1681/ASN.2013111216
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Urology / Nephrology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
American Society of Nephrology. "A single dose of mood stabilizing drug helped restore kidney function in mice with acute kidney injury." Medical News Today. MediLexicon, Intl., 13 Jan. 2014. Web.
18 Apr. 2014. <http://www.medicalnewstoday.com/releases/271049>
American Society of Nephrology. (2014, January 13). "A single dose of mood stabilizing drug helped restore kidney function in mice with acute kidney injury." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271049.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.